Analyses of Human Samples Collected in Clinical Trials
Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
2 other identifiers
observational
2,579
2 countries
17
Brief Summary
Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes. The purpose of this study is to conduct further analyses on these existing samples from clinical trials that are being performed outside of, but in collaboration with, the National Cancer Institute.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2003
Longer than P75 for all trials
17 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 2, 2003
CompletedFirst Submitted
Initial submission to the registry
June 19, 2006
CompletedFirst Posted
Study publicly available on registry
June 21, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 17, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 26, 2020
CompletedMarch 30, 2020
March 1, 2020
16.7 years
June 19, 2006
March 27, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Drug and/or metabolite concentration
To quantitate drug and/or metabolite concentrations in human blood samples
Ongoing
Secondary Outcomes (1)
Pharmacological behavior of agents
Ongoing
Study Arms (1)
1/ patients
Patients on approved clinical trials
Eligibility Criteria
Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer@@@
You may not qualify if:
- None anticipated at this time.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (17)
Childrens National Medical Center
Washington D.C., District of Columbia, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
University of Chicago
Chicago, Illinois, 60637, United States
University of Maryland, Baltimore
Baltimore, Maryland, 21201-1595, United States
Johns Hopkins Medical Center
Baltimore, Maryland, 21231, United States
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Mayo Clinic, Rochester
Rochester, Minnesota, 55905, United States
Case Western Reserve University
Cleveland, Ohio, 44106-2602, United States
University of Maryland at Amish Research Clinic, Lancaster
Lancaster, Pennsylvania, United States
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Hillman Cancer Center at University of Pittsburg Cancer Institute
Pittsburgh, Pennsylvania, 15261, United States
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425, United States
McGuire Veterans Administration Medical Center
Richmond, Virginia, 23249, United States
Massey Cancer Center, Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Leiden University Medical Center
Leiden, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
William D Figg, Pharm.D.
National Cancer Institute (NCI)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 19, 2006
First Posted
June 21, 2006
Study Start
July 2, 2003
Primary Completion
March 17, 2020
Study Completion
March 26, 2020
Last Updated
March 30, 2020
Record last verified: 2020-03